{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T06:05:20Z","timestamp":1793858720912,"version":"4.6.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jsbmb.2017.03.014","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T13:33:31Z","timestamp":1489844011000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Comparison of intravaginal 6.5 mg (0.50%) prasterone, 0.3 mg conjugated estrogens and 10 \u03bcg estradiol on symptoms of vulvovaginal atrophy"],"prefix":"10.1016","volume":"174","author":[{"given":"David F.","family":"Archer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernand","family":"Labrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Montesino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Martel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2017.03.014_bib0005","doi-asserted-by":"crossref","first-page":"C113","DOI":"10.1016\/0303-7207(91)90116-A","article-title":"Intracrinology","volume":"78","author":"Labrie","year":"1991","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0010","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3109\/13697137.2015.1070477","article-title":"Each tissue becomes master of its sex steroid environment at menopause","volume":"18","author":"Labrie","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0015","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/13697137.2012.733983","article-title":"DHEA and intracrinology at menopause, a positive choice for evolution of the human species","volume":"16","author":"Labrie","year":"2013","journal-title":"Climacteric"},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0020","first-page":"14","article-title":"DHEA after menopause\u2014sole source of sex steroids and potential sex steroid deficiency treatment","volume":"19","author":"Labrie","year":"2010","journal-title":"Menopause Manage."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0025","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1677\/joe.1.06264","article-title":"Is DHEA a hormone? Starling review","volume":"187","author":"Labrie","year":"2005","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jsbmb.2014.06.001","article-title":"All sex steroids are made intracellularly in peripheral tissues by the mechanisms of intracrinology after menopause","volume":"145","author":"Labrie","year":"2015","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0035","article-title":"Science of intracrinology in postmenopausal women","volume":"24","author":"Labrie","year":"2017","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.jsbmb.2017.03.014_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/13697137.2015.996846","article-title":"Menopause\u2014natural selection or modern disease?","volume":"18","author":"Panay","year":"2015","journal-title":"Climacteric"},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0045","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jsbmb.2013.08.002","article-title":"Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens","volume":"138","author":"Labrie","year":"2013","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0050","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jsbmb.2008.11.004","article-title":"Comparable amounts of sex steroids are made outside the gonads in men and women: strong lesson for hormone therapy of prostate and breast cancer","volume":"113","author":"Labrie","year":"2009","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"1","key":"10.1016\/j.jsbmb.2017.03.014_bib0055","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/gme.0b013e3181e195a6","article-title":"Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary?","volume":"18","author":"Labrie","year":"2011","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0060","series-title":"Androgens in Gynecological Practice","first-page":"64","article-title":"Androgens in postmenopausal women: their practically exclusive intracrine formation and inactivation in peripheral tissues","author":"Labrie","year":"2015"},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0065","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jsbmb.2016.03.016","article-title":"Serum steroid concentrations remain within normal postmenopausal values in women receiving daily 6.5mg intravaginal prasterone for 12 weeks","volume":"159","author":"Martel","year":"2016","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0070","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3109\/13697137.2010.535226","article-title":"Intravaginal dehydroepiandrosterone (DHEA Prasterone), a highly efficient treatment of dyspareunia","volume":"14","author":"Labrie","year":"2011","journal-title":"Climacteric"},{"issue":"9","key":"10.1016\/j.jsbmb.2017.03.014_bib0075","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1097\/GME.0000000000000428","article-title":"Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepaindrosterone (prasterone)","volume":"22","author":"Archer","year":"2015","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.jsbmb.2017.03.014_bib0080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/GME.0000000000000571","article-title":"Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause","volume":"23","author":"Labrie","year":"2016","journal-title":"Menopause"},{"issue":"4","key":"10.1016\/j.jsbmb.2017.03.014_bib0085","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/gme.0b013e3181a48c4e","article-title":"Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally","volume":"16","author":"Bachmann","year":"2009","journal-title":"Menopause"},{"issue":"1","key":"10.1016\/j.jsbmb.2017.03.014_bib0090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/01.AOG.0000296714.12226.0f","article-title":"Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial","volume":"111","author":"Bachmann","year":"2008","journal-title":"Obstet. Gynecol."},{"issue":"5","key":"10.1016\/j.jsbmb.2017.03.014_bib0095","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/AOG.0b013e31818aa7c3","article-title":"Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet","volume":"112","author":"Simon","year":"2008","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0100","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.maturitas.2015.02.005","article-title":"Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study","volume":"81","author":"Labrie","year":"2015","journal-title":"Maturitas"},{"issue":"4","key":"10.1016\/j.jsbmb.2017.03.014_bib0105","doi-asserted-by":"crossref","first-page":"590","DOI":"10.3109\/13697137.2014.992012","article-title":"Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy","volume":"18","author":"Bouchard","year":"2015","journal-title":"Climacteric"},{"issue":"3","key":"10.1016\/j.jsbmb.2017.03.014_bib0110","first-page":"245","article-title":"Vaginal dryness in the menopausal woman (physiological and psychological aspects)","volume":"28","author":"Rossin-Amar","year":"2000","journal-title":"Gynecol. Obstet. Fertil."},{"issue":"5","key":"10.1016\/j.jsbmb.2017.03.014_bib0115","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3109\/13697137.2014.946279","article-title":"Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society","volume":"17","author":"Portman","year":"2014","journal-title":"Climacteric"},{"issue":"6","key":"10.1016\/j.jsbmb.2017.03.014_bib0120","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S0015-0282(01)01791-5","article-title":"Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate","volume":"75","author":"Utian","year":"2001","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0125","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/gme.0b013e31819e8e2d","article-title":"Intravaginal dehydroepiandrosterone (Prasterone) a physiological and highly efficient treatment of vaginal atrophy","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0130","unstructured":"Guidelines for Industry, Estrogen and estrogen\/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms \u2013 Recommendations for clinical evaluation, Center for Drug Evaluation and Research (CDER), January (2003)."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0135","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/009286151004400505","article-title":"Statistical considerations for the efficacy assessment of clinical studies of vulvar and vaginal atrophy","volume":"44","author":"Chen","year":"2010","journal-title":"Drug Inf. J."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0140","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1097\/gme.0b013e31819e8930","article-title":"Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration","volume":"16","author":"Labrie","year":"2009","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.jsbmb.2017.03.014_bib0145","first-page":"117","article-title":"Serum steroids remain within the same normal postmenopausal values during 12-month intravaginal 0.50% DHEA","volume":"24","author":"Ke","year":"2015","journal-title":"Horm. Mol. Biol. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0150","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.jsbmb.2015.08.016","article-title":"Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration","volume":"154","author":"Ke","year":"2015","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0155","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jsbmb.2016.12.007","article-title":"Androgens in women are essentially made from DHEA in each peripheral tissue according to intracrinology","volume":"168","author":"Labrie","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0160","first-page":"1","article-title":"Is vulvovaginal atrophy due to a lack of both estrogens and androgens?","volume":"24","author":"Labrie","year":"2017","journal-title":"Menopause"},{"issue":"3","key":"10.1016\/j.jsbmb.2017.03.014_bib0165","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00042192-200007030-00005","article-title":"17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis","volume":"7","author":"Rioux","year":"2000","journal-title":"Menopause"},{"issue":"5","key":"10.1016\/j.jsbmb.2017.03.014_bib0170","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/01.gme.0000227401.98933.0b","article-title":"A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women","volume":"13","author":"Long","year":"2006","journal-title":"Menopause"},{"issue":"2","key":"10.1016\/j.jsbmb.2017.03.014_bib0175","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jsbmb.2005.02.018","article-title":"Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina","volume":"96","author":"Berger","year":"2005","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.jsbmb.2017.03.014_bib0180","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1111\/j.1743-6109.2012.02895.x","article-title":"Effects of ovariectomy and dehydroepiandrosterone (DHEA) on vaginal innervation in the rat","volume":"9","author":"Pelletier","year":"2012","journal-title":"J. Sex. Med."},{"issue":"8","key":"10.1016\/j.jsbmb.2017.03.014_bib0185","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/jsm.12219","article-title":"Androgenic action of dehydroepiandrosterone (DHEA) on nerve density in the ovariectomized rat vagina","volume":"10","author":"Pelletier","year":"2013","journal-title":"J. Sex. Med."},{"issue":"1","key":"10.1016\/j.jsbmb.2017.03.014_bib0190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/en.2005-0870","article-title":"Differential effects of estradiol, progesterone, and testosterone on vaginal structural integrity","volume":"147","author":"Pessina","year":"2006","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.jsbmb.2017.03.014_bib0195","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1111\/jsm.13045","article-title":"Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy","volume":"12","author":"Labrie","year":"2015","journal-title":"J. Sex. Med."},{"issue":"3","key":"10.1016\/j.jsbmb.2017.03.014_bib0200","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0960-0760(98)00052-1","article-title":"Effect of dehydroepiandrosterone on vaginal and uterine histomorphology in the rat","volume":"6","author":"Sourla","year":"1998","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"2","key":"10.1016\/j.jsbmb.2017.03.014_bib0205","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/acel.12309","article-title":"Intramuscular sex steroid hormones are associated with skeletal muscle strength and power in women with different hormonal status","volume":"14","author":"Pollanen","year":"2015","journal-title":"Aging Cell"},{"issue":"4","key":"10.1016\/j.jsbmb.2017.03.014_bib0210","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1474-9726.2011.00701.x","article-title":"Differential influence of peripheral and systemic sex steroids on skeletal muscle quality in pre- and postmenopausal women","volume":"10","author":"Pollanen","year":"2011","journal-title":"Aging Cell"},{"issue":"2","key":"10.1016\/j.jsbmb.2017.03.014_bib0215","doi-asserted-by":"crossref","first-page":"E577","DOI":"10.1152\/ajpendo.00367.2006","article-title":"Expression of steroidogenic enzymes and synthesis of sex steroid hormones from DHEA in skeletal muscle of rats","volume":"292","author":"Aizawa","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076017300791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076017300791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:54:34Z","timestamp":1760745274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076017300791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":43,"alternative-id":["S0960076017300791"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2017.03.014","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of intravaginal 6.5mg (0.50%) prasterone, 0.3mg conjugated estrogens and 10\u03bcg estradiol on symptoms of vulvovaginal atrophy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2017.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}